

Mometasone Ointment Formulation

Version 1.8 Revision Date: 09.04.2021 SDS Number: 1751225-00009 Date of last issue: 10.10.2020
Date of first issue: 14.06.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking**1.1 Product identifier**

Trade name : Mometasone Ointment Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.
30 Hudson Street, 33rd floor
07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification**2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Skin irritation, Category 2	H315: Causes skin irritation.
Eye irritation, Category 2	H319: Causes serious eye irritation.
Long-term (chronic) aquatic hazard, Category 2	H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements**Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms :  

Signal word : Warning

Hazard statements : H315 Causes skin irritation.
H319 Causes serious eye irritation.
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear protective gloves/ eye protection/ face protection.

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

Response:

P332 + P313 If skin irritation occurs: Get medical advice/attention.

P337 + P313 If eye irritation persists: Get medical advice/attention.

P391 Collect spillage.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients**3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
2-Methyl-2,4-pentanediol	107-41-5 203-489-0 603-053-00-3	Skin Irrit. 2; H315 Eye Irrit. 2; H319	>= 10 - < 20
Mometasone	83919-23-7	Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 100	>= 0,1 - < 0,25

For explanation of abbreviations see section 16.

SECTION 4: First aid measures**4.1 Description of first aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

- Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

- Risks : Causes skin irritation.
Causes serious eye irritation.

4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures**5.1 Extinguishing media**

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

- Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

- Specific hazards during fire-fighting : Vapours may form explosive mixtures with air.
Exposure to combustion products may be a hazard to health.

- Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage**7.1 Precautions for safe handling**

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
 Strong oxidizing agents
 Organic peroxides
 Explosives
 Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection**8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
2-Methyl-2,4-pentanediol	107-41-5	TWA OEL-RL	25 ppm 125 mg/m ³	ZA OEL
Further information: Recommended Limit				
		STEL OEL-RL	25 ppm 125 mg/m ³	ZA OEL
Further information: Recommended Limit				
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
2-Methyl-2,4-pentanediol	Workers	Inhalation	Long-term systemic effects	44,4 mg/m ³
	Workers	Inhalation	Long-term local effects	49 mg/m ³
	Workers	Inhalation	Acute local effects	98 mg/m ³
	Workers	Skin contact	Long-term systemic effects	42 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	7,8 mg/m ³
	Consumers	Inhalation	Long-term local effects	25 mg/m ³

SAFETY DATA SHEET



Mometasone Ointment Formulation



Version 1.8 Revision Date: 09.04.2021 SDS Number: 1751225-00009 Date of last issue: 10.10.2020
Date of first issue: 14.06.2017

	Consumers	Inhalation	Acute local effects	49 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	15 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	1,5 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9,33 mg/kg food
2-Methyl-2,4-pentanediol	Fresh water	0,429 mg/l
	Marine water	0,043 mg/l
	Freshwater - intermittent	4,29 mg/l
	Sewage treatment plant	20 mg/l
	Fresh water sediment	1,59 mg/kg dry weight (d.w.)
	Marine sediment	0,159 mg/kg dry weight (d.w.)
	Soil	0,066 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Combined particulates and organic vapour type (A-P)

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties**

Appearance	:	ointment
Colour	:	white to off-white
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	> 93,3 °C
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not classified as a flammability hazard
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids)	:	Not applicable
Molecular weight	:	No data available

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

Particle size : No data available

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Vapours may form explosive mixture with air.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure : Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**2-Methyl-2,4-pentanediol:**

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
LD50 (Mouse): > 2.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3,3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3,2 mg/l
 Exposure time: 4 h
 Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg
 Application Route: Subcutaneous
 Symptoms: Breathing difficulties

Skin corrosion/irritation

Causes skin irritation.

Components:**2-Methyl-2,4-pentanediol:**

Result : Skin irritation
 Remarks : Based on harmonised classification in EU regulation 1272/2008, Annex VI

Mometasone:

Species : Rabbit
 Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**2-Methyl-2,4-pentanediol:**

Species : Rabbit
 Result : Irritation to eyes, reversing within 21 days

Mometasone:

Species : Rabbit
 Result : No eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**2-Methyl-2,4-pentanediol:**

Test Type : Maximisation Test
 Exposure routes : Skin contact
 Species : Guinea pig
 Method : OECD Test Guideline 406
 Result : negative

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

Mometasone:

Test Type : Maximisation Test
 Exposure routes : Dermal
 Species : Guinea pig
 Assessment : Does not cause skin sensitisation.
 Result : negative
 Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

Germ cell mutagenicity

Not classified based on available information.

Components:**2-Methyl-2,4-pentanediol:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

 Test Type: In vitro mammalian cell gene mutation test
 Method: OECD Test Guideline 476
 Result: negative

 Test Type: Chromosome aberration test in vitro
 Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

 Test Type: Chromosomal aberration
 Test system: Chinese hamster lung cells
 Result: negative

 Test Type: Chromosomal aberration
 Test system: Chinese hamster ovary cells
 Result: positive

 Test Type: Mouse Lymphoma
 Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
 Species: Mouse
 Application Route: Oral
 Result: negative

 Test Type: Chromosomal aberration
 Species: Rat
 Cell type: Bone marrow
 Result: negative

 Test Type: unscheduled DNA synthesis assay
 Species: Rat

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

Cell type: Liver cells

Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**Mometasone:**

Species : Rat
 Application Route : Inhalation
 Exposure time : 2 Years
 Dose : 0.067 mg/kg body weight
 Result : negative

Species : Mouse
 Application Route : Inhalation
 Exposure time : 19 Months
 Dose : 0.160 mg/kg body weight
 Result : negative

Reproductive toxicity

Not classified based on available information.

Components:**2-Methyl-2,4-pentanediol:**

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening test
 Species: Rat
 Application Route: Ingestion
 Method: OECD Test Guideline 421
 Result: negative

Effects on foetal development : Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Ingestion
 Method: OECD Test Guideline 414
 Result: negative

Mometasone:

Effects on fertility : Test Type: Fertility
 Species: Rat
 Application Route: Subcutaneous
 Fertility: NOAEL: 0,015 mg/kg body weight
 Symptoms: Reduced embryonic survival, Reduced foetal weight
 Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal development : Test Type: Embryo-foetal development
 Species: Mouse

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

Application Route: Subcutaneous
 Embryo-foetal toxicity: LOAEL: 0,06 mg/kg body weight
 Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Dermal
 Embryo-foetal toxicity: LOAEL: 0,3 mg/kg body weight
 Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development
 Species: Rabbit
 Application Route: Dermal
 Embryo-foetal toxicity: LOAEL: 0,15 mg/kg body weight
 Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Subcutaneous
 Embryo-foetal toxicity: LOAEL: 0,15 mg/kg body weight
 Result: Effects on newborn

Test Type: Embryo-foetal development
 Species: Rabbit
 Application Route: Oral
 Embryo-foetal toxicity: LOAEL: 0,7 mg/kg body weight
 Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:**Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

STOT - repeated exposure

Not classified based on available information.

Components:**Mometasone:**

Exposure routes : inhalation (dust/mist/fume)
 Target Organs : Immune system, Liver, Kidney, Skin
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

Repeated dose toxicity**Components:****2-Methyl-2,4-pentanediol:**

Species	:	Rat
NOAEL	:	>= 450 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Method	:	OECD Test Guideline 408

Mometasone:

Species	:	Rat
NOAEL	:	0,005 mg/kg
LOAEL	:	0,3 mg/kg
Application Route	:	Oral
Exposure time	:	30 d
Target Organs	:	Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	:	Dog
LOAEL	:	0,5 mg/kg
Application Route	:	Oral
Exposure time	:	30 d
Target Organs	:	Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	:	Rat
NOAEL	:	0,00013 mg/l
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	90 d
Target Organs	:	Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species	:	Dog
NOAEL	:	0,0005 mg/l
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	90 d
Target Organs	:	Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity

Not classified based on available information.

Components:**Mometasone:**

Not applicable

Experience with human exposure**Components:****2-Methyl-2,4-pentanediol:**

Eye contact	:	Target Organs: Eyes Symptoms: Irritation
-------------	---	---

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

Further information**Components:****Mometasone:**

Remarks : Dermal absorption possible

SECTION 12: Ecological information**12.1 Toxicity****Components:****2-Methyl-2,4-pentandiol:**

Toxicity to fish : LC50 (Gambusia affinis (Mosquito fish)): 8.510 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 2.800 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC10 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : NOEC : 200 mg/l
Exposure time: 10 d

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0,11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

EC50 (Americamysis): > 5 mg/l
 Exposure time: 96 h
 Method: US-EPA OPPTS 850.1035
 Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3,2 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201
 Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 1.000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209
 Remarks: No toxicity at the limit of solubility

NOEC : 1.000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209
 Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC: 0,00014 mg/l
 Exposure time: 32 d
 Species: Pimephales promelas (fathead minnow)
 Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0,34 mg/l
 Exposure time: 21 d
 Species: Daphnia magna (Water flea)
 Method: OECD Test Guideline 211
 Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 100

12.2 Persistence and degradability**Components:****2-Methyl-2,4-pentanediol:**

Biodegradability : Result: Readily biodegradable.
 Biodegradation: 81 %
 Exposure time: 28 d
 Method: OECD Test Guideline 301F

Mometasone:

Biodegradability : Result: Not readily biodegradable.
 Biodegradation: 50 %
 Exposure time: 28 d
 Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)
 Method: OECD Test Guideline 111

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

12.3 Bioaccumulative potential**Components:****2-Methyl-2,4-pentanediol:**

Partition coefficient: n-octanol/water : log Pow: 0
Remarks: Calculation

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107,1
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4,68

12.4 Mobility in soil**Components:****Mometasone:**

Distribution among environmental compartments : log Koc: 4,02

12.5 Results of PBT and vPvB assessment**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations**13.1 Waste treatment methods**

Product : Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

SECTION 14: Transport information**14.1 UN number**

ADN	:	UN 3077
ADR	:	UN 3077
RID	:	UN 3077
IMDG	:	UN 3077
IATA	:	UN 3077

14.2 UN proper shipping name

ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
IATA	:	Environmentally hazardous substance, solid, n.o.s. (Mometasone)

14.3 Transport hazard class(es)

ADN	:	9
ADR	:	9
RID	:	9
IMDG	:	9
IATA	:	9

14.4 Packing group

ADN		
Packing group	:	III
Classification Code	:	M7
Hazard Identification Number	:	90
Labels	:	9
ADR		
Packing group	:	III
Classification Code	:	M7
Hazard Identification Number	:	90
Labels	:	9
Tunnel restriction code	:	(-)
RID		

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

Packing group : III
 Classification Code : M7
 Hazard Identification Number : 90
 Labels : 9

IMDG

Packing group : III
 Labels : 9
 EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo aircraft) : 956
 Packing instruction (LQ) : Y956
 Packing group : III
 Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passenger aircraft) : 956
 Packing instruction (LQ) : Y956
 Packing group : III
 Labels : Miscellaneous

14.5 Environmental hazards**ADN**

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

AICS : not determined

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H315 : Causes skin irritation.
 H319 : Causes serious eye irritation.
 H360Df : May damage the unborn child. Suspected of damaging fertility.
 H373 : May cause damage to organs through prolonged or repeated exposure if inhaled.
 H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Aquatic Chronic : Long-term (chronic) aquatic hazard
 Eye Irrit. : Eye irritation
 Repr. : Reproductive toxicity
 Skin Irrit. : Skin irritation
 STOT RE : Specific target organ toxicity - repeated exposure
 ZA OEL : South Africa. Hazardous Chemical Substances Regulations, Occupational Exposure Limits
 ZA OEL / TWA OEL-RL : Long term occupational exposure limits - recommended limit
 ZA OEL / STEL OEL-RL : Short term occupational exposure limits - recommended limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse)

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.8	09.04.2021	1751225-00009	Date of first issue: 14.06.2017

Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Skin Irrit. 2	H315
Eye Irrit. 2	H319
Aquatic Chronic 2	H411

Classification procedure:

Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN